until you understand that this represents aprx 6% of the float.,or 3% of total shares and that certain parties will soon approach owning a majority of the company.Sure it could be sold and going private may not happpen.GHDX is a rare bird indeed.Take note that the SP was pushed to near the years low after being up 25% most of the rest of the year to facilitate not only this ASR but a large purchase by insiders in recent trades.
The buying last month was the Baker Brothers but this move has yielded no 5% SEC docs.I have a different take.The cap gains tax was paid for with this push down,.You can see it all the big holdings of the #$%$.Next year will be a min 50% gain if the co isnt sold or gone private
Terry - take a look in the Oregonian online and review an article about Oregon Health Sciences University (OHSU) and their genomic tests for cancer. My concern is that the field of genomic testing is getting crowded. Will GHDX need to lower prices to stay competitive?
I'm the trader in the family and my wife the scientist just flew to D.C.(Ill ask her)))
I do see however ,this is a stripped down test,targeting ?what Cancers?
Like trading there are numbers and probabilities, .and GHDX testing gives the best probabilities.
Genomic Health specifically has targeted Colon and breast,and the juggernaut of health care cost
article: "Under the FDA's system, drug approval requires a new years-long trial for each disease or type of tumor."
jmho- this compassionate care from the University will need to do extensive trialing to match GHDX % probabilities./Insurance coverage
No doubt there is competition and the OHSU story ,to this investor seems like clinical work years out....and money
Genomic Health spends the most of anyone on R&D.